Press Releases

After an inspection of Julphar facilities, the Gulf Health Council and the Pharmaceutical & Herbal Medicine Registration & Quality Control Admin, Ministry of Health, State of Kuwait has lifted the temporary suspension on the export of Julphar products to Bahrain and Kuwait

- Rights issue is part of Julphar's capital restructuring to improve the capital base and debt profile. - The company will offer 500 million new shares with a nominal value of AED 1. Ras Al Khaimah, UAE; June 1, 2020: Gulf Pharmaceutical Industries PSC (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, announced today the launch of its AED 500 million rights issue as the company progresses on its ambitious turnaround plan. The rights issue is set to improve the company’s capital position and debt profile and will provide the financial foundation for the successful implementation of the company’s medium-term growth strategy.

After an inspection of Julphar facilities, Saudi Food and Drug Authority has lifted the temporary suspension on the export of Julphar products to Saudi Arabia

Capital reduction, followed by an up to AED 500 million rights issue, will extinguish accumulated losses and is part of a comprehensive transformation programme